Displaying 13 - 24 of 31
Metabolism, Alcohol & Toxicity
The contribution of metabolic co-morbidities and hepatic thyroid hormone dysregulation to the pathophysiology of NASH

The contribution of metabolic co-morbidities and hepatic thyroid hormone dysregulation to the pathophysiology of NASH

Webcasts
View
Immune-Mediated and Cholestatic Diseases
Unmet needs in PBC: the patient perspective

Unmet needs in PBC: the patient perspective

Webcasts
View
Immune-Mediated and Cholestatic Diseases
Welcome & objectives

Welcome & objectives

Webcasts
View
Immune-Mediated and Cholestatic Diseases
Key considerations in the management of cirrhosis in PBC

Key considerations in the management of cirrhosis in PBC

Webcasts
View
Immune-Mediated and Cholestatic Diseases
Q&A

Q&A

Webcasts
View
Immune-Mediated and Cholestatic Diseases
Does our increasing knowledge of PBC pathogenesis affect early management?

Does our increasing knowledge of PBC pathogenesis affect early management?

Webcasts
View
Immune-Mediated and Cholestatic Diseases
Enhancing clinical care strategies in PBC

Enhancing clinical care strategies in PBC

Webcasts
View
Metabolism, Alcohol & Toxicity
NASH: An evolution in treatment response tools

NASH: An evolution in treatment response tools

Webcasts
View
Metabolism, Alcohol & Toxicity
Why we need to talk about NASH

Why we need to talk about NASH

Webcasts
View
Metabolism, Alcohol & Toxicity
Hepatic consequences of metabolic dysregulation: NAFLD and NASH

Hepatic consequences of metabolic dysregulation: NAFLD and NASH

Webcasts
View
Metabolism, Alcohol & Toxicity
Looking ahead: how to identify high-risk patients

Looking ahead: how to identify high-risk patients

Webcasts
View
Metabolism, Alcohol & Toxicity
Navigating the NASH healthcare system: global insights and challenges (panel discussion and Q&A)

Navigating the NASH healthcare system: global insights and challenges (panel discussion and Q&A)

Webcasts
View
Displaying 13 - 24 of 31